收购资产，罕见的遗传病。

Rhythm Pharmaceuticals (NASDAQ:RYTM) announced Monday that its subsidiary, Rhythm Pharmaceuticals Netherlands B.V. acquired Xinvento B.V., a Dutch biotech focused on developing treatments for the rare genetic disease congenital hyperinsulinism (CHI). $Rhythm制药(RYTM)$